PRKCI and neoplasm: Despite over 30% of ovarian cancer patients harbor PRKCI amplification and reported tumor-promoting role of PKCι in experimental ovarian cancer models, we failed to detect clear association between the status of PRKCI amplification and survivals of ovarian cancer patients (Supplementary Data Fig. S1).